Date | Time | Source | Headline | Symbol | Company |
07/18/2024 | 1:00PM | iHub Newswire | FeaturedNorth Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton | | |
07/19/2024 | 8:30AM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:ESPR | Esperion Therapeutics Inc |
07/19/2024 | 8:29AM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:ESPR | Esperion Therapeutics Inc |
07/17/2024 | 3:22PM | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NASDAQ:ESPR | Esperion Therapeutics Inc |
07/17/2024 | 3:11PM | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NASDAQ:ESPR | Esperion Therapeutics Inc |
07/16/2024 | 8:00AM | GlobeNewswire Inc. | New Digital First Marketing Campaign from Esperion Alerts Patients with Uncontrolled LDL Cholesterol to the “Lipid Lurkers” Inside Their Arteries | NASDAQ:ESPR | Esperion Therapeutics Inc |
06/28/2024 | 7:00AM | GlobeNewswire Inc. | Esperion Announces Monetization of European Royalties and Concurrent Payoff and Termination of Existing Revenue Interest Facility | NASDAQ:ESPR | Esperion Therapeutics Inc |
06/18/2024 | 3:19PM | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NASDAQ:ESPR | Esperion Therapeutics Inc |
06/18/2024 | 3:09PM | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NASDAQ:ESPR | Esperion Therapeutics Inc |
05/28/2024 | 4:16PM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:ESPR | Esperion Therapeutics Inc |
05/24/2024 | 4:18PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:ESPR | Esperion Therapeutics Inc |
05/24/2024 | 4:14PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:ESPR | Esperion Therapeutics Inc |
05/24/2024 | 4:13PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:ESPR | Esperion Therapeutics Inc |
05/23/2024 | 9:00AM | GlobeNewswire Inc. | Esperion to Participate in Upcoming June Investor Conferences | NASDAQ:ESPR | Esperion Therapeutics Inc |
05/22/2024 | 8:00AM | GlobeNewswire Inc. | First-In-Class Cholesterol-Lowering Treatment NILEMDO® (NEXLETOL® in the U.S.) and Its Combination with Ezetimibe, NUSTENDI® (NEXLIZET® in the U.S.), Approved In Europe To Treat Hypercholesterolemia and Significantly Reduce Cardiovascular Risk | NASDAQ:ESPR | Esperion Therapeutics Inc |
05/20/2024 | 4:14PM | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:ESPR | Esperion Therapeutics Inc |
05/20/2024 | 6:00AM | GlobeNewswire Inc. | Bempedoic Acid Met Primary Endpoint of Phase 3 Trial in Japan for the Treatment for Hypercholesterolemia | NASDAQ:ESPR | Esperion Therapeutics Inc |
05/17/2024 | 3:08PM | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NASDAQ:ESPR | Esperion Therapeutics Inc |
05/14/2024 | 8:00AM | GlobeNewswire Inc. | Esperion Receives Five Year Patent Extension for Bempedoic Acid, Contained in NEXLETOL® and NEXLIZET® | NASDAQ:ESPR | Esperion Therapeutics Inc |
05/10/2024 | 4:00PM | GlobeNewswire Inc. | Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | NASDAQ:ESPR | Esperion Therapeutics Inc |
05/08/2024 | 4:31PM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:ESPR | Esperion Therapeutics Inc |
05/07/2024 | 8:50AM | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:ESPR | Esperion Therapeutics Inc |
05/07/2024 | 7:29AM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:ESPR | Esperion Therapeutics Inc |
05/07/2024 | 6:00AM | GlobeNewswire Inc. | Esperion Reports First Quarter 2024 Financial Results | NASDAQ:ESPR | Esperion Therapeutics Inc |
04/29/2024 | 8:00AM | GlobeNewswire Inc. | Esperion to Participate in Upcoming May Investor Conferences | NASDAQ:ESPR | Esperion Therapeutics Inc |
04/23/2024 | 8:00AM | GlobeNewswire Inc. | Esperion to Report First Quarter 2024 Financial Results on May 7 | NASDAQ:ESPR | Esperion Therapeutics Inc |
04/07/2024 | 2:45PM | GlobeNewswire Inc. | Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity | NASDAQ:ESPR | Esperion Therapeutics Inc |
04/01/2024 | 8:00AM | GlobeNewswire Inc. | Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024 | NASDAQ:ESPR | Esperion Therapeutics Inc |
03/26/2024 | 8:00AM | GlobeNewswire Inc. | Esperion to Participate in 23rd Annual Needham Virtual Healthcare Conference | NASDAQ:ESPR | Esperion Therapeutics Inc |
03/25/2024 | 4:00PM | GlobeNewswire Inc. | Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24 | NASDAQ:ESPR | Esperion Therapeutics Inc |